The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis
In this video, Alexander Lesokhin, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the results of a post-hoc analysis from the MagnetisMM-3 trial (NCT04649359), which aimed to evaluate the feasibility and safety of prolonged interruption of elranatamab treatment in patients with relapsed/refractory (R/R) multiple myeloma (MM). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The MagnetisMM3 trial is a Phase 2 registrational study evaluating elranatamab. This is a BCMAxCD3 bispecific T-cell engager. The trial enrolled patients that were exposed to a proteasome inhibitor, an IMID, and an anti-CD38 antibody, and either naive to BCMA-directed therapy or had previously received BCMA-directed antibody drug conjugates or CAR T-cell therapy. Among the patients that were BCMA-naive, the response rate was 61%...
The MagnetisMM3 trial is a Phase 2 registrational study evaluating elranatamab. This is a BCMAxCD3 bispecific T-cell engager. The trial enrolled patients that were exposed to a proteasome inhibitor, an IMID, and an anti-CD38 antibody, and either naive to BCMA-directed therapy or had previously received BCMA-directed antibody drug conjugates or CAR T-cell therapy. Among the patients that were BCMA-naive, the response rate was 61%. The CR rate was 37%. This led to the approval of elranatamab for use in patients with triple refractory multiple myeloma.
Of the 187 patients, some patients came off of treatment for a variety of adverse events. So we performed a post hoc analysis to ask the question of whether or not treatment interruption was feasible and safe for these patients. The enrollment criteria for the post-hoc analysis was stopping elranatamab and having follow-up data for six or more months. And this, from the 187 patients, 30 patients met these criteria. Median time to stopping elranatamab was approximately 13 months. Median time of follow-up after stopping was about 18 months and ranged up to, I think, up to three years. At the time of data cut, only three patients had progressed. And two patients that were in CR progressed at two or three years. And one patient that was in the PR at the time of stopping progressed at approximately one year. 78% of patients have not had a need to resume therapy at the time of data cut. So I think the take-home message from this study is that treatment interruption is quite feasible. And, you know, of course, additional study will need to be, you know, performed to evaluate whether or not we can plan treatment interruption, not wait for an adverse event among patients that perhaps achieve a CR and whether or not that will result in similar durability of efficacy as ongoing continuous elranatamab therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
